HemaCare Slows Losses After Cutting R&D; Costs
HemaCare Corp., a Sherman Oaks-based provider of blood products and services, reported a narrowed loss for the second quarter ending June 30.
The company reported a quarterly loss of $139,000, compared to a loss of $516,000 during the second quarter last year. The company said revenues for the second quarter of 1995 were down 11% to $2.55 million, compared to $2.87 million during the same period a year earlier.
For the six-month period, HemaCare posted a $187,000 loss, compared to a loss of $1.2 million during the same period in 1994. Revenues for the latest six months decreased slightly to $5.3 million, compared to $5.5 million during the first six months of 1994.
HemaCare said the narrowed loss came from the curtailment of research and development expenses.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
